Nurse Practitioner, Family · Dallas, TX
NPI
1083894919
Since 2007
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
5201 Harry Hines Blvd
Dallas, TX, 75235
Phone (214) 590-5694
Groups this clinician bills Medicare through
Medicare paid, 2024
$6,929
137 services
Medicare patients, 2024
58
Average age 62
Drug cost, 2024
$1.2M
2,495 prescriptions
Company payments, 2025
$149
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Dalgliesh D Thomas was code 99214 (office e&m - established), 29 times for 18 patients. In total Dalgliesh D Thomas billed 137 services in 8 codes, and Medicare paid $6,929.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-08-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 29 | 18 | $63.45 | $1,840 |
| 99213 Office E&M - Established | Office | 19 | 11 | $35.39 | $672 |
| 99214 Office E&M - Established | Facility | 16 | 13 | $52.56 | $841 |
By year: 2022 $7,744 for 132 services; 2023 $7,639 for 141 services; 2024 $6,929 for 137 services.
Medicare prescription drug claims, 2024
In 2024, the drug Dalgliesh D Thomas prescribed most often to Medicare patients was Ozempic (Semaglutide), with 295 prescriptions and refills. In total Dalgliesh D Thomas wrote 2,495 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 295 | 369 | 58 | $330K |
| Mounjaro Tirzepatide | 197 | 202 | 39 | $197K |
| Jardiance Empagliflozin | 118 | 263 | 44 | $144K |
| Trulicity Dulaglutide | 111 | 131 | 24 | $118K |
| Metformin Hcl Generic | 111 | 212 | 34 | $672 |
| Metformin Hcl Er Metformin Hcl | 99 | 166 | 32 | $767 |
| Atorvastatin Calcium Generic | 93 | 228 | 44 | $727 |
| Tresiba Flextouch U-200 Insulin Degludec | 92 | 157 | 21 | $78K |
| Novolog Flexpen Insulin Aspart | 92 | 151 | 34 | $19K |
| Ultra-Fine Short Pen Needle Pen Needle, Diabetic | 87 | 151 | 36 | $6,647 |
| Techlite Pen Needle Pen Needle, Diabetic | 78 | 153 | 44 | $1,708 |
| Tresiba Flextouch U-100 Insulin Degludec | 68 | 173 | 25 | $29K |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 67 | 138 | 21 | $23K |
| Gabapentin Generic | 64 | 112 | 23 | $711 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 61 | 115 | 29 | $5,395 |
Brand drugs: 1,498 claims; generic drugs: 660 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Dalgliesh D Thomas $149 ($149 in general payments such as food, travel and fees) from 1 company. The largest payer was Dexcom, Inc. with $149.
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. DXCM | 1 | $149 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.